eMedicine Specialties > Thoracic Surgery > Cardiac

Ventricular Septal Rupture Following Myocardial Infarction: Treatment

Author: Shabir Bhimji, MD, PhD, Locum Cardiothoracic and Vascular Surgeon, Saudi Arabia and Middle East Hospitals
Contributor Information and Disclosures

Updated: Nov 7, 2008

Treatment

Medical Therapy

Institute pharmacological therapy in an attempt to hemodynamically stabilize the patient. The purpose of the therapy is to reduce afterload on the heart and to increase forward cardiac output.

Vasodilators may be used in an attempt to decrease the left-to-right shunt associated with the mechanical defect and thus increase cardiac output. Intravenous nitroglycerin can be used as a vasodilator and may provide improved myocardial blood flow in patients with significant ischemic cardiac disease.

Inotropic agents used alone may increase cardiac output; however, without changes in the ratio of pulmonary to systemic flow (Qp-to-Qs), they markedly increase left ventricular work and myocardial oxygen consumption. The profound level of cardiogenic shock in some patients precludes vasodilator treatment, often necessitating vasopressor support. Inotropic agents and vasopressors markedly increase left ventricular work and myocardial oxygen consumption. Vasopressor agents also increase systemic afterload and further increase the Qp-to-Qs ratio, thus lowering cardiac output and greatly augmenting myocardial oxygen consumption. Nevertheless, the profound level of cardiogenic shock in some patients may preclude vasodilator treatment.

Intra-aortic balloon counterpulsation (IABCP) offers the most important means of temporary hemodynamic support. IABCP reduces left ventricular afterload, thus increasing systemic cardiac output and decreasing the Qp-to-Qs ratio. IABCP also facilitates diastolic augmentation with an increase in coronary blood flow, resulting in improved oxygen supply. IABCP is not a substitute for urgent intervention, and, in patients with cardiogenic shock, it should be followed by immediate intervention. Patients with ventricular septal rupture (VSR) do not die of cardiac failure; they die as a result of end organ failure. Only by shortening the duration of shock can the high risk of mortality be prevented.

Achieving hemodynamic stability prior to surgery is very beneficial, but prolonged attempts to improve the patient's hemodynamic status can be hazardous.5

This aggressive approach often results in temporary stability of these extremely ill patients; however, in general, these benefits are brief and patients may rapidly deteriorate. Therefore, early diagnosis and rapid surgical intervention should be planned. Only approximately 10-15% of patients can be treated with conservative treatment for a period of 2-4 weeks, after which surgery can be performed at a greatly reduced risk.

Surgical Therapy

The first operations for repair of postinfarction VSR used an approach through the right ventricle, with an incision of the right ventricular outflow tract as was used to repair some congenital ventriculoseptal defects (VSDs). This approach proved inadequate because of limited exposure for lesions at the apex of the heart, injury to normal right ventricular muscle, interruption of coronary collateral vessels, and failure to excise the infarcted tissue.

Subsequently, a transinfarction approach was described. This technique, first pioneered by Heimbecker, incorporates infarctectomy, aneurysmectomy, and repair of the ventricular septal perforation. The technique of closure of these defects has resulted in several procedures. The choice of procedure is determined by the location of the defect. Most defects are anteroapical, and closure uses a technique of buttressing the defect with viable muscle from the adjacent anterior left ventricular wall. Smaller defects located high in the ventricular septum are closed with a Dacron patch.

The less common high posterior septal or inferior defect is approached through the inferior portion of the heart, usually in the distribution of the posterior descending coronary branch of the right coronary artery. The incision is made in the area of maximal infarction, which is usually on the right ventricular side of the septum. A well-proven principle of repair of these defects is the use of a synthetic patch closure to prevent tension.

Associated Procedures

Concomitant coronary artery bypass

Controversy surrounds the issue of whether to perform coronary artery bypass in patients undergoing emergent postinfarction ventricular septal repair. Some authors have shown no benefit to coronary artery bypass surgery and have found that cardiac catheterization in ill patients is time consuming and risks contrast injury to the kidney. However, others have used a selective approach to cardiac catheterization.

In patients who probably do not have a history of angina or previous MI, cardiac catheterization is deferred. Cardiac catheterization findings help confirm and quantitate the presence of a shunt and reveal pulmonary artery pressure and resistance values. The left ventriculogram helps determine the location and number of VSDs, define left ventricular function, and also assess mitral valve function. Most surgeons perform bypass in patients with VSR and have shown a significant improvement in survival.

Mitral valve replacement

Occasionally, significant mitral valve regurgitation may be associated with acute VSR, particularly when the infarction is posterior. The mitral valve must be replaced under such circumstances. Replacement is usually best accomplished through the left ventriculotomy incision using interrupted, pledged mattress sutures.

Left ventricular aneurysm

When a left ventricular aneurysm is associated with postinfarction VSR, it is excised as the initial step in the surgery. After repair of the VSR, the aneurysm is generally repaired.

Preoperative Details

Preoperative management is directed toward rapid resuscitation and stabilization of the patient and preparation for surgery. The goals are to (1) reduce systemic vascular resistance (thereby decreasing the left-to-right shunt), (2) maintain a stable cardiac output and blood pressure, and (3) maintain coronary artery blood flow.

Preoperative treatment of patients with postinfarction VSR is summarized as follows:

  • Transfer patients to an intensive care unit for resuscitation.
  • Place a Swan-Ganz catheter to help manage hemodynamics.
  • Decrease the systemic vascular resistance and the left-to-right shunt with vasodilators.
  • Maintain cardiac output and organ perfusion with inotropic agents.
  • Maintain coronary artery blood flow.
  • Use IABCP to decrease myocardial oxygen consumption, decrease afterload, and increase coronary artery perfusion.
  • Use mechanical ventilation as required.
  • Use echocardiography to help determine the site of septal rupture.
  • Use cardiac catheterization to help determine the presence of coronary disease.

Intraoperative Details

Principles associated with the evolution of techniques for the closure of postinfarction VSR are summarized as follows:

  • Determine and understand the anatomy and location of the VSR and any associated coronary artery pathology.
  • Expeditiously establish hypothermic total cardiopulmonary bypass, and pay attention to myocardial protection with cardioplegia.
  • Use a transinfarction approach to the VSR, with the site of ventriculotomy determined by the location of the transmural infarction.
  • Inspect the papillary muscles, and concomitantly replace the mitral valve only if frank papillary muscle rupture is present.
  • Trim the left ventricular margins back to viable muscle.
  • Conservatively trim the right ventricular muscle.
  • Close the VSR without tension with the use of prosthetic material.
  • Buttress the suture line with Teflon pledgets.

Postoperative Details

Patients who require an intra-aortic balloon pump preoperatively appear to benefit from postoperative support with the device for 24-72 hours. Some of these patients demonstrate a small persistent or recurrent left-to-right shunt. Because of the large amount of prosthetic material used to repair the septal perforation, anticoagulation therapy in these patients is recommended by some surgeons for a period of 6-8 weeks.

Follow-up

For excellent patient education resources, visit eMedicine's Heart Center. Also, see eMedicine's patient education articles Ventricular Septal Defect and Heart Attack.

More on Ventricular Septal Rupture Following Myocardial Infarction

Overview: Ventricular Septal Rupture Following Myocardial Infarction
Workup: Ventricular Septal Rupture Following Myocardial Infarction
Treatment: Ventricular Septal Rupture Following Myocardial Infarction
Follow-up: Ventricular Septal Rupture Following Myocardial Infarction
References

References

  1. David TE. Operative management of postinfarction ventricular septal defect. Semin Thorac Cardiovasc Surg. Oct 1995;7(4):208-13. [Medline].

  2. Gaudiani VA, Miller DG, Stinson EB, et al. Postinfarction ventricular septal defect: an argument for early operation. Surgery. Jan 1981;89(1):48-55. [Medline].

  3. Daggett WM, Buckley MJ, Akins CW, et al. Improved results of surgical management of postinfarction ventricular septal rupture. Ann Surg. Sep 1982;196(3):269-77. [Medline].

  4. Heitmiller R, Jacobs ML, Daggett WM. Surgical management of postinfarction ventricular septal rupture. Ann Thorac Surg. Jun 1986;41(6):683-91. [Medline].

  5. Deja MA, Szostek J, Widenka K, et al. Post infarction ventricular septal defect - can we do better?. Eur J Cardiothorac Surg. Aug 2000;18(2):194-201. [Medline].

  6. Cummings RG, Califf R, Jones RN, et al. Correlates of survival in patients with postinfarction ventricular septal defect. Ann Thorac Surg. Jun 1989;47(6):824-30. [Medline].

  7. Muehrcke DD, Daggett WM. Current surgical approach to acute ventricular septal rupture. Adv Card Surg. 1995;6:69-90. [Medline].

  8. Cooley DA. Repair of the difficult ventriculotomy. Ann Thorac Surg. Jan 1990;49(1):150-1. [Medline].

  9. Daggett WM. Surgical technique for early repair of posterior ventricular septal rupture. J Thorac Cardiovasc Surg. Aug 1982;84(2):306-12. [Medline].

  10. Ellis CJ, Parkinson GF, Jaffe WM, et al. Good long-term outcome following surgical repair of post-infarction ventricular septal defect. Aust N Z J Med. Aug 1995;25(4):330-6. [Medline].

  11. Jacobs ML, Daggett WM. Postinfarction ventricular septal rupture. In: Grillo HC, Austen WG, Wilkins EW Jr, Mathisen DJ, Vlahakes GJ, eds. Current Therapy in Cardiothoracic Surgery. 2nd ed. Toronto, Ont: BC Decker; 1989:. 435-7.

  12. Komeda M, Fremes SE, David TE. Surgical repair of postinfarction ventricular septal defect. Circulation. Nov 1990;82(5 Suppl):IV243-7. [Medline].

  13. Landzberg MJ, Lock JE. Transcatheter management of ventricular septal rupture after myocardial infarction. Semin Thorac Cardiovasc Surg. Apr 1998;10(2):128-32. [Medline].

  14. Piwnica A. Update in surgical treatment of acute post infarction VSDs and MIs. Eur J Cardiothorac Surg. 1995;9(3):117-9. [Medline].

  15. von Segesser LK, Siebenmann R, Schneider K, et al. Postinfarction ventricular septal defect--surgical strategies and results. Thorac Cardiovasc Surg. Apr 1989;37(2):72-5. [Medline].

Further Reading

Keywords

VSR, ventricular rupture, ventricle rupture, post-MI VSR, post MI ventricular rupture, postinfarct ventricular septal rupture, postinfarct VSR, postinfarction VSR, anteroapical septal rupture, posterior septal rupture, transmural infarction, loud systolic murmur, left-to-right shunt, left heart catheterization, intraaortic balloon pump, intra-aortic balloon pump, IABP, intraaortic balloon counterpulsation, IABCP, intra-aortic balloon counterpulsation cardiogenic shock, ventriculotomy, aneurysmectomy, patch repair, coronary revascularization, recurrent ventricular septal defect, ventriculoseptal defect, VSD, ventricular septal defect, congestive heart failure, CHF, coronary heart disease, CAD, heart failure

Contributor Information and Disclosures

Author

Shabir Bhimji, MD, PhD, Locum Cardiothoracic and Vascular Surgeon, Saudi Arabia and Middle East Hospitals
Shabir Bhimji, MD, PhD is a member of the following medical societies: American Cancer Society, American College of Chest Physicians, American Lung Association, and Texas Medical Association
Disclosure: Nothing to disclose.

Medical Editor

Jeffrey C Milliken, MD, Chief, Division of Cardiothoracic Surgery, University of California at Irvine Medical Center; Clinical Professor, Department of Surgery, University of California at Irvine School of Medicine
Jeffrey C Milliken, MD is a member of the following medical societies: Alpha Omega Alpha, American Association for Thoracic Surgery, American College of Cardiology, American College of Chest Physicians, American College of Surgeons, American Heart Association, American Society for Artificial Internal Organs, California Medical Association, International Society for Heart and Lung Transplantation, Phi Beta Kappa, Society of Thoracic Surgeons, Southwest Oncology Group, and Western Surgical Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Shreekanth V Karwande, MBBS, Chair, Professor, Department of Surgery, Division of Cardiothoracic Surgery, University of Utah School of Medicine and Medical Center
Shreekanth V Karwande, MBBS is a member of the following medical societies: American Association for Thoracic Surgery, American College of Chest Physicians, American College of Surgeons, American Heart Association, Society of Critical Care Medicine, Society of Thoracic Surgeons, and Western Thoracic Surgical Association
Disclosure: Nothing to disclose.

CME Editor

Rajalaxmi McKenna, MD, FACP, Consulting Staff, Department of Medicine, Southwest Medical Consultants, SC, Good Samaritan Hospital, Advocate Health Systems
Rajalaxmi McKenna, MD, FACP is a member of the following medical societies: American Society of Clinical Oncology, American Society of Hematology, and International Society on Thrombosis and Haemostasis
Disclosure: Nothing to disclose.

Chief Editor

Mary C Mancini, MD, PhD, Professor, Department of Surgery, Louisiana State University Health Sciences Center
Mary C Mancini, MD, PhD is a member of the following medical societies: American Heart Association, American Medical Association, American Thoracic Society, Association for Academic Surgery, Association for Surgical Education, International College of Surgeons, International Society for Heart and Lung Transplantation, New York Academy of Sciences, Phi Beta Kappa, and Southern Thoracic Surgical Association
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.